Livagen 20mg
Research-grade Livagen 20mg. 99% purity, third-party tested with published COA.
Ships from USA
1–3 day delivery
Free Shipping
On orders $150+
Peptide Handling & Storage Guide
Storage temperature, shelf life & reconstitution (PDF)
99%+ Purity
COA included
Same-Day Shipping
Orders before 2PM EST
Secure Checkout
SSL encrypted
Shipment Protection
Lost or damaged — reshipped free
Compound Information
- Type
- Synthetic tetrapeptide bioregulator
- Molecular Formula
- C18H31N5O9
- Molecular Weight
- 461.5 g/mol
- Purity
- 99%
- Sequence
- Lys-Glu-Asp-Ala (KEDA)
Reference chemistry (free base) from public chemical databases and peer-reviewed literature. For laboratory research identification only.
Research Use Only. This vial is bound for the lab bench — supplied for in-vitro scientific work exclusively, never for administration to any person or animal.
About Livagen
Livagen is the tetrapeptide Lys-Glu-Asp-Ala (KEDA), one of the short synthetic peptides investigated by V. Kh. Khavinson and colleagues for effects on chromatin organization and gene activity in aged cells.
In peer-reviewed studies (Bulletin of Experimental Biology and Medicine, 2002 and 2004), Livagen applied to lymphocytes from elderly donors was reported to activate ribosomal genes and decondense pericentromeric heterochromatin, releasing genes repressed by age-related chromatin condensation. This reproducible primary evidence concerns chromatin and ribosomal-gene changes in cultured human lymphocytes; it is preclinical and from a single research group. Broader claims tied to the "liver" association implied by the name are not established by the primary literature and are not asserted here.
Frequently Asked Questions
What is Livagen?
Livagen is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Ala (KEDA), part of the Khavinson class of short peptide bioregulators. It is supplied for research use only and is not approved for human use.
What is Livagen peptide?
It is a four-residue synthetic peptide studied in preclinical research on chromatin organization. In published lymphocyte studies it was reported to activate ribosomal genes and decondense age-condensed heterochromatin — laboratory findings, not demonstrated health effects.
What is the sequence of Livagen?
Livagen is the tetrapeptide Lys-Glu-Asp-Ala, abbreviated KEDA.
What has Livagen been studied for?
Peer-reviewed research (Bulletin of Experimental Biology and Medicine, 2002 and 2004) examined Livagen’s effects on chromatin in lymphocytes from elderly donors, reporting activation of ribosomal genes and decondensation of heterochromatin. This work is preclinical; no efficacy or safety in humans is established.
Is Livagen approved for human use?
No. Livagen has no regulatory approval as a drug, supplement, or therapeutic. It is sold for laboratory research use only and should not be used for diagnosis, treatment, or human consumption.
Research & References
Independent databases and peer-reviewed literature for Livagen. Provided for research reference only.
External resources are independent and not affiliated with or endorsed by PHIOGEN. Listed for laboratory research reference only.
